Comparative Study of the Effects of Chamomile (Matricaria Chamomilla L.) and Cabergoline on Idiopathic Hyperprolactinemia: A Pilot Randomized Controlled Trial

Document Type : Research article


1 School of Traditional Medicine, Tehran University of Medical Sciences, Tehran, Iran.

2 School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

3 Institute of Family Health, Maternal, Fetal and Neonatal Research Center, Tehran University of Medical Sciences, Tehran, Iran.

4 Vali-e-Asr Hospital, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.


Chamomile is a fascinating plant quoted in several traditional medicine texts, which has
broad-spectrum pharmacological activity and medicinal uses. The aim of this study was to
assess the efficacy of chamomile syrup in reducing serum prolactin in women with idiopathic
hyperprolactinemia. The study was a randomized, controlled clinical trial that was conducted
on 56 women with idiopathic hyperprolactinemia for a study period of four weeks. Patients
were randomly enrolled in two parallel arms and were treated by chamomile syrup at a dose
of 5 mL twice daily or cabergoline tablet orally at a dose of 0.25 mg twice weekly. Serum
prolactin levels were measured at baseline and the end of the 4-week study period. Any report
of adverse events was also recorded. Results revealed that within the cabergoline group the
reduction in the mean prolactin level was significantly greater than that of the chamomile
group (
p <0.0001). It was also found that decline in the mean prolactin level was statistically
significant within the chamomile group (
p <0.0001). Chamomile syrup seems to be effective
on serum prolactin reduction in women with idiopathic hyperprolactinemia. However, studies
with a larger sample size and for a longer follow-up period are recommended.


Main Subjects

Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL,
Montori VM, Schlechte JA and Wass JA. Diagnosis
and treatment of hyperprolactinemia: an Endocrine
Society clinical practice guideline. J. Clin. Endocrinol.
Metab. (2011) 96: 273-88.
Ignacak A, Kasztelnik M, Sliwa T, Korbut R, Rajda K
and Guzik T. Prolactin–not only lactotrophin. A “new”
view of the “old” hormone. J. Physiol. Pharmacol.
(2012) 63: 435-43.
Capozzi A, Scambia G, Pontecorvi A and Lello S.
Hyperprolactinemia: pathophysiology and therapeutic
approach. Gynecol. Endocrinol. (2015) 31: 506-10.
Pala NA, Laway BA, Misgar RA and Dar RA.
Metabolic abnormalities in patients with prolactinoma:
response to treatment with cabergoline. Diabetol.
Metab. Syndr. (2015) 7: 1.
Haring R, Friedrich N, Völzke H, Vasan RS, Felix
SB, Dörr M, zu Schwabedissen HEM, Nauck M
and Wallaschofski H. Positive association of
serum prolactin concentrations with all-cause and
cardiovascular mortality. Eur. Heart J. (2014) 35:
Tworoger SS, Sluss P and Hankinson SE. Association
between plasma prolactin concentrations and risk of
breast cancer among predominately premenopausal
women Cancer Res. (2006) 66: 2476-82.
Fernandez I, Touraine P and Goffin V. Prolactin and
human tumourogenesis. J. Neuroendocrinol. (2010)
22: 771-7.
Verhelst J and Abs R. Hyperprolactinemia. Treat
Endocrinol. (2003) 2: 23-32.
De Bellis A, Colao A, Pivonello R, Savoia A, Battaglia
M, Ruocco G, Tirelli G, Lombardi G, Bellastella A
and Bizzarro A. Antipituitary antibodies in idiopathic
hyperprolactinemic patients. Ann. N. Y. Acad. Sci.
(2007) 1107: 129-35.
Dekkers OM, Lagro J, Burman P, Jørgensen JO, Romijn
JA and Pereira AM. Recurrence of hyperprolactinemia
after withdrawal of dopamine agonists: systematic
review and meta-analysis. J. Clin. Endocrinol. Metab.
(2010) 95: 43-51.
Saadat N, Esmaily H, Abbasinazari M, Tohidi M,
Salamzadeh J, Hadaegh F, Tolabi M, Kalantar-Hormozi
M and Dibaj M. Does twice-weekly cabergoline
improve anthropometrical and biochemical profiles in
prediabetes? A randomized double-blind clinical trial
pilot study. Iran. J. Pharm. Res. (2015) 14: 77.
Coulter ID and Willis EM. The rise and rise of
complementary and alternative medicine: a sociological
perspective. Med. J. Aust. (2004) 180: 587-90.
Bahadori S, Salamzadeh J, Kamalinejad M, Ardekani
MRS, Keshavarz M and Ahmadzadeh A. Study of
the Effect of an Oral Formulation of Fig and Olive
on Rheumatoid Arthritis (RA) Remission Indicators:
A Randomized Clinical Trial. Iran. J. Pharm. Res.
(2016) 15: 537.
Sharaibi OJ, Ogundipe OT, Afolayan AJ and Aworinde
 Kabiri M et al. / IJPR (2019), 18 (3): 1612-1621
DO. Ethnobotanical survey and phytochemical
analysis of medicinal plants used for the treatment of
hyperprolactinemia in Lagos State, Nigeria. J. Med.
Plant Res. (2014) 8: 1284-8.
Hasani-Ranjbar S, Vahidi H, Taslimi S, Karimi N,
Larijani B and Abdollahi M. A systematic review on
the efficacy of herbal medicines in the management
of human drug-induced hyperprolactinemia; potential
sources for the development of novel drugs. Int. J.
Pharmacol. (2010) 6: 691-5.
Jones WP, Chin Y-W and Kinghorn AD. The role of
pharmacognosy in modern medicine and pharmacy.
Curr. Drug Targets (2006) 7: 247-64.
Ibn Sina. Al- Qanun fi al- tibb [The Canon of
Medicine]. Muhammad Amin al - Dinnawi (ed.) 2nd ed.
Dar al- Kotob Al- Ilmiyah Publisher, Beirut, Lebanon
(2009) 383-382.
Franke R and Schilcher H. Relevance And Use of
Chamomile (Matricaria Recutita L.). International
Society for Horticultural Science (ISHS); 2007,
Leuven, Belgium.
Srivastava JK, Shankar E and Gupta S. Chamomile:
A herbal medicine of the past with bright future. Mol.
Med. Rep. (2010) 3: 895.
McKay DL and Blumberg JB. A review of the
bioactivity and potential health benefits of Chamomile
Tea (Matricaria recutita L.). Phytother. Res. (2006)
20: 519–30
Petronilho S, Maraschin M, Coimbra MA and Rocha
SM. In vitro and in vivo studies of natural products:
A challenge for their valuation. The case study of
chamomile (Matricaria recutita L.). Ind. Crops
Prod. (2012) 40: 1-12.
Cvetanović A, Švarc-Gajić J, Zeković Z, Savić S, Vulić
J, Mašković P and Ćetković G. Comparative analysis
of antioxidant, antimicrobiological and cytotoxic
activities of native and fermented chamomile ligulate
flower extracts. Planta (2015) 242: 721-32.
Srivastava JK, Pandey M and Gupta S. Chamomile,
a novel and selective COX-2 inhibitor with antiinflammatory activity. Life Sci. (2009) 85: 663-9.
Srivastava JK and Gupta S. Antiproliferative and
apoptotic effects of chamomile extract in various
human cancer cells. J. Agric. Food Chem. (2007) 55:
Kassi E, Papoutsi Z, Fokialakis N, Messari I, Mitakou
S and Moutsatsou P. Greek plant extracts exhibit
selective estrogen receptor modulator (SERM)-like
properties. J. Agric. Food Chem. (2004) 52: 6956-61.
Rafraf M, Zemestani M and Asghari-Jafarabadi M.
Effectiveness of chamomile tea on glycemic control
and serum lipid profile in patients with type 2 diabetes.
J. Endocrinol. Invest. (2015) 38: 163-70.
Zand RSR, Jenkins DJ and Diamandis EP. Effects
of natural products and nutraceuticals on steroid
hormone-regulated gene expression. Clin. Chim. Acta
(2001) 312: 213-9.
Avallone R, Zanoli P, Puia G, Kleinschnitz M, Schreier
P and Baraldi M. Pharmacological profile of apeignin,
a flavonoid isolated from Matricaria chamomilla.
Biochem. Pharmacol. (2000) 59: 1387-94.
Viola H, Wasowski C, De Stein ML, Wolfman
C, Silveira R, Dajas F, Medina J and Paladini A.
Apigenin, a component of Matricaria recutita flowers,
is a central benzodiazepine receptors-ligand with
anxiolytic effects. Planta Med. (1995) 61: 213-6.
Nakazawa T, Yasuda T, Ueda J and Ohsawa K.
Antidepressant-like effects of apigenin and 2, 4,
5-trimethoxycinnamic acid from Perilla frutescens in
the forced swimming test. Biol. Pharm. Bull. (2003)
26: 474-80.
Sharifi F, Simbar M, Mojab F and Majd HA.
Comparison of the effects of Matricaria chamomila
(Chamomile) extract and mefenamic acid on the
intensity of premenstrual syndrome. Complement.
Ther. Clin. Pract. (2014) 20: 81-8.
Sharifi F, Simbar M, Mojab F and Alavi Majd H.
Comparison of the Effects of Matricaria chamomila
(Chamomile) Extract and Mefenamic Acid on the
Intensity of Mastalgia Associated With Premenstrual
Syndrome. Women›s Health Bull. (2014) 1: e20042.
Zargaran A, Borhani-Haghighi A, Faridi P,
Daneshamouz S, Kordafshari G and Mohagheghzadeh
A. Potential effect and mechanism of action of
topical chamomile (Matricaria chammomila L.) oil
on migraine headache: A medical hypothesis. Med.
Hypotheses (2014) 83: 566-9.
Abu Bakr Muhammad Ibn Zakariya Al Razi. Al Havi
[Liber Continent] Vol. 3. Muhammad Muhammad
Esmail (ed.) Dar al- kotob Al- Ilmiyah Publishers,
Beirut, Lebanon (2000) 7.
Aghili Khorasani Shirazi SMH. Makhzan al-Advyh.
1nd ed. Bavardaran Publisher, Tehran (2001) 194-193.
Jabbari M, Hashempur MH, Razavi SZE, Shahraki
HR, Kamalinejad M and Emtiazy M. Efficacy and
short-term safety of topical Dwarf Elder (Sambucus
ebulus L.) versus diclofenac for knee osteoarthritis:
A randomized, double-blind, active-controlled trial. J.
Ethnopharmacol. (2016) 188: 80-6.
Baba SA and Malik SA. Determination of total
phenolic and flavonoid content, antimicrobial and
antioxidant activity of a root extract of Arisaema
jacquemontii Blume. J. Taibah. Univ. Sci. (2015) 9:
Mulinacci N, Romani A, Pinelli P, Vincieri F and
Prucher D. Characterization of Matricaria recutita
L. Flower extracts by HPLC-MS and HPLC-DAD
analysis. Chromatographia (2000) 51: 301-7.
Herb-Drug Interactions: German Chamomile.
Medicinal Plants. [serial online] 2011 [cited 2017 may
21]. Available from: URL:
Huang W-Y, Cai Y-Z and Zhang Y. Natural phenolic
compounds from medicinal herbs and dietary plants:
potential use for cancer prevention. Nutr. Cancer
(2009) 62: 1-20.
Shukla S and Gupta S. Apigenin: a promising molecule
for cancer prevention. Pharm. Res. (2010) 27: 962-78.
Effects of chamomile syrup in reducing prolactin
Pourabbas R and Delazar A. The effect of German
chamomile mouthwash on dental plaque and gingival
inflammation. Iran. J. Pharm. Res. (2010) 105-9.
Kempuraj D, Tagen M, Iliopoulou B, Clemons
A, Vasiadi M, Boucher W, House M, Wolfberg A
and Theoharides T. Luteolin inhibits myelin basic
protein‐induced human mast cell activation and mast
cell‐dependent stimulation of Jurkat T cells. Br. J.
Pharmacol. (2008) 155: 1076-84.
Kumar S, Mansel R, Scanlon M, Hughes L, Edwards
CA, Woodhead J and Newcombe R. Altered
responses of prolactin, luteinizing hormone and
follicle stimulating hormone secretion to thyrotrophin
releasing hormone/gonadotrophin releasing hormone
stimulation in cyclical mastalgia. Br. J.Surg. (1984)
71: 870-3.
Mansel R and Dogliotti L. European multicentre trial
of bromocriptine in cyclical mastalgia. Lancet (1990)
335: 190-3.
Wuttke W, Jarry H, Christoffel V, Spengler B and
Seidlova-Wuttke D. Chaste tree (Vitex agnus-castus)–
pharmacology and clinical indications. Phytomedicine
(2003) 10: 348-57.
van Die MD, Burger HG, Teede HJ and Bone KM.
Vitex agnus-castus extracts for female reproductive
disorders: a systematic review of clinical trials. Planta
Med. (2013) 79: 562-75.
Kilicdag E, Tarim E, Bagis T, Erkanli S, Aslan E,
Ozsahin K and Kuscu E. Fructus agni casti and
bromocriptine for treatment of hyperprolactinemia and
mastalgia. Int. J. Gynaecol. Obstet. (2004) 85: 292-3.
Jarry H, Leonhardt S, Gorkow C and Wuttke W.
In vitro prolactin but not LH and FSH release is
inhibited by compounds in extracts of Agnus castus:
direct evidence for a dopaminergic principle by the
dopamine receptor assay. Exp. Clin. Endocrinol.
(1994) 102: 448-54.
Verhelst J, Abs R, Maiter D, van den Bruel A,
Vandeweghe M, Velkeniers B, Mockel J, Lamberigts
G, Petrossians P and Coremans P. Cabergoline in
the treatment of hyperprolactinemia: a study in 455
patients. J. Clin. Endocrinol. Metab. (1999) 84: 2518-